CN118019750A - 用于局部递送治疗剂的药物递送系统以及其用途 - Google Patents

用于局部递送治疗剂的药物递送系统以及其用途 Download PDF

Info

Publication number
CN118019750A
CN118019750A CN202280062538.8A CN202280062538A CN118019750A CN 118019750 A CN118019750 A CN 118019750A CN 202280062538 A CN202280062538 A CN 202280062538A CN 118019750 A CN118019750 A CN 118019750A
Authority
CN
China
Prior art keywords
drug delivery
delivery system
mmol
group
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280062538.8A
Other languages
English (en)
Chinese (zh)
Inventor
吴国龙
张纬江
冯立春
张�浩
李大峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Chunan Biomedical Technology Co ltd
Original Assignee
Shanghai Chunan Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Chunan Biomedical Technology Co ltd filed Critical Shanghai Chunan Biomedical Technology Co ltd
Publication of CN118019750A publication Critical patent/CN118019750A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280062538.8A 2021-09-16 2022-09-14 用于局部递送治疗剂的药物递送系统以及其用途 Pending CN118019750A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/118666 2021-09-16
CN2021118666 2021-09-16
PCT/CN2022/118658 WO2023040879A1 (en) 2021-09-16 2022-09-14 Drug delivery system for locally delivering therapeutic agents and uses thereof

Publications (1)

Publication Number Publication Date
CN118019750A true CN118019750A (zh) 2024-05-10

Family

ID=85602430

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280062538.8A Pending CN118019750A (zh) 2021-09-16 2022-09-14 用于局部递送治疗剂的药物递送系统以及其用途

Country Status (9)

Country Link
US (1) US20240398963A1 (https=)
EP (1) EP4402152A1 (https=)
JP (1) JP2024533034A (https=)
KR (1) KR20240056728A (https=)
CN (1) CN118019750A (https=)
AU (1) AU2022348759A1 (https=)
CA (1) CA3227319A1 (https=)
IL (1) IL311382A (https=)
WO (1) WO2023040879A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119735627A (zh) * 2024-12-25 2025-04-01 西北农林科技大学 甾体并3，4二氢吡咯吡嗪酮衍生物及其合成方法与应用
WO2026002095A1 (en) * 2024-06-26 2026-01-02 Coval Biopharma (Shanghai) Co., Ltd. Drug delivery system for locally controlled release of therapeutic agents and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009096749A (ja) * 2007-10-16 2009-05-07 Konica Minolta Holdings Inc コレステロール誘導体、リポソーム及びｘ線用造影剤
EP3142705B1 (en) * 2014-05-15 2020-08-19 Agency For Science, Technology And Research Polymer-flavonoid conjugate and uses thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026002095A1 (en) * 2024-06-26 2026-01-02 Coval Biopharma (Shanghai) Co., Ltd. Drug delivery system for locally controlled release of therapeutic agents and uses thereof
CN119735627A (zh) * 2024-12-25 2025-04-01 西北农林科技大学 甾体并3，4二氢吡咯吡嗪酮衍生物及其合成方法与应用

Also Published As

Publication number Publication date
EP4402152A1 (en) 2024-07-24
US20240398963A1 (en) 2024-12-05
JP2024533034A (ja) 2024-09-12
WO2023040879A1 (en) 2023-03-23
KR20240056728A (ko) 2024-04-30
CA3227319A1 (en) 2023-03-23
IL311382A (en) 2024-05-01
AU2022348759A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
CN115867319B (zh) 用于局部递送治疗剂的药物递送系统以及其用途
JP7693948B2 (ja) ε－ポリ－Ｌ－リジンをベースとする薬物コンジュゲート、その中間体及びその用途
JP2003527443A (ja) ポリグルタミン酸−カンプトセシン結合体およびその調製方法
CN118019750A (zh) 用于局部递送治疗剂的药物递送系统以及其用途
CN121443581A (zh) 用于肌肉特异性递送的可电离脂质
CN101948500A (zh) 喜树碱20位偶合胆酸的新衍生物
AU2021421161B2 (en) Ligand compounds, conjugates, and applications thereof
US20030216289A1 (en) Polyglutamic acid-camptothecin conjugates and methods of preparation
CN112300099A (zh) 药物的缩酮衍生物及其制备方法、药物组合物和用途
HK40110475A (zh) 用於局部递送治疗剂的药物递送系统以及其用途
RU2849554C2 (ru) Конъюгат производного ε-поли-l-лизина с лекарственным средством, промежуточные соединения и их применение
RU2847196C9 (ru) Система доставки лекарственных средств для локальной доставки терапевтических агентов и ее применения
RU2847196C1 (ru) Система доставки лекарственных средств для локальной доставки терапевтических агентов и ее применения
CN111868097B (zh) 司坦唑醇与透明质酸的缀合物
CA3237677C (en) Epsilon-poly-l-lysine-based drug conjugate, intermediate thereof, and application thereof
RU2819894C1 (ru) Лигандные соединения, конъюгаты и их применение
HK40107352B (zh) 用於局部递送治疗剂的药物递送系统以及其用途
HK40107352A (zh) 用於局部递送治疗剂的药物递送系统以及其用途
AU2024202698A1 (en) Three cluster galactose type compound, conjugate, making method and use thereof
WO2026002095A1 (en) Drug delivery system for locally controlled release of therapeutic agents and uses thereof
BR112024008991B1 (pt) Conjugado de derivado de poli(e-l-lisina)-fármaco, e, composto
HK40069355B (zh) 化合物、缀合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40110475

Country of ref document: HK